Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data.

Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data. Cancer Treat Rev. 2010 May; 36(3):216-23.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.